ResMed Upgraded to Zacks Rank #2 (Buy) on Rising Earnings Estimates

Analyst
โดย Zacks Investment Research·Read original
Summary · why it matters

ResMed has been upgraded to a Zacks Rank #2 (Buy), reflecting an upward trend in earnings estimates. The Zacks Consensus Estimate for the fiscal year ending June 2026 has increased 1.3% over the past three months, with analysts steadily raising their projections. The upgrade places ResMed in the top 20% of Zacks-covered stocks, indicating potential for near-term price appreciation.

Impact on stocks 1

Cloud & Digital Infrastructure▲ · 1 stocks
ResMed Inc
RMD
▲ PositiveCapitalrelevance

Upgraded to Zacks Rank #2 (Buy) based on rising earnings estimates, indicating positive analyst sentiment and potential price appreciation.

© 2026 MarketDXNews